This integrated bioinformatic analysis demonstrated that GATA1-4, and 6 may be new prognostic biomarkers, and GATA2/5/6 may be potential targets for personalized therapy for patients with LC. Here, GATA2 is linked to laryngotracheoesophageal cleft.